CONFIRM Trial
https://www.southampton.ac.uk/ctu/trialportfolio/listoftrials/confirm.page
CONFIRM is a double blind randomised phase III trial comparing nivolumab (anti‐PD‐1 antibody) monotherapy versus placebo for one year. The treatment allocation ratio is 2:1 (treatment: placebo).
Existing samples:
- Mesothelioma, malignant (morphologic (abnormality)
Contact Information
- Email:
- confirmtrial@soton.ac.uk
- Address:
-
Southampton Clinical Trials Unit
Southampton General Hospital
Tremona Road
Southampton
Hampshire
SO16 6YD
UK
Annual Statistics
| Year | Access Requests Received | Access Requests Approved | ||||
|---|---|---|---|---|---|---|
| Internal | External | Commercial | Internal | External | Commercial | |
| 2015 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2016 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2017 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2018 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2019 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A | N/A | N/A |